Azacitidine in CMML: Matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival

作者：Pleyer Lisa; Germing Ulrich; Sperr Wolfgang R; Linkesch Werner; Burgstaller Sonja; Stauder Reinhard; Girschikofsky Michael; Schreder Martin; Pfeilstocker Michael; Lang Alois; Sliwa Thamer; Geissler Dietmar; Schlick Konstantin; Placher Sorko Gudrun; Theiler Georg; Thaler Josef; Mitrovic Martina; Neureiter Daniel; Valent Peter; Greila Richard^*

来源：Leukemia Research, 2014, 38(4): 475-483.

DOI：10.1016/j.leukres.2014.01.006

• Matched-pair analysis
• CMML
• Chronic myelomonocytic leukemia
• Azacitidine
• Austrian Azacitidine Registry

Recent data suggest that azacitidine may be beneficial in CMML. We report on 48 CMML-patients treated with azacitidine. Overall response rates were high (70% according to IWG-criteria, including 22% complete responses). Monocyte count and cytogenetics adversely affected survival, whereas age, WHO-type, FABtype, and spleen size did not. Matched-pair analyses revealed a trend for higher two-year-survival for azacitidine as compared to best supportive care (62% vs. 41%, p = 0.067) and longer OS for azacitidine firstline vs. hydroxyurea first-line (p = 0.072, median OS 27.7 vs. 6.2 months). This report reinforces existing evidence that azacitidine is safe and efficacious in both myelodysplastic and myeloproliferative CMML.

• 出版日期2014-4